Pi-Cardia today announced the first commercial procedures with its ShortCut leaflet modification device for enabling heart ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides ...

Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCut™ - the world's first ...

Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCuttm - the world's first ...

The collaboration aims to upskill over 300 cardiologists and radiologists in echocardiography and MRI, with a focus on ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides interventional cardiologists, cardiothoracic surgeons, and heart teams with ...

Therefore, we examined the additional value of circulating fibrosis markers as a putative biomarker platform to identify patients with aortic stenosis undergoing transcatheter aortic valve replacement ...

Valve‐in‐valve transcatheter aortic valve replacement (TAVR) is a recognized alternative for treating the structural valve deterioration of bioprosthetic valves. Recent guidelines and trials have ...

First dedicated leaflet modification solution to enable TAVR in patients at risk of coronary obstruction Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treati ...

Introduction Aortic stenosis is a significant cause of morbidity and mortality in older patients. The advent of transcatheter aortic valve implantation (TAVI) offers an alternative to surgical aortic ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.